Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial)

Aksentijevich, 2009, An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist, N. Engl. J. Med., 360, 2426, 10.1056/NEJMoa0807865 Alexander, 2012, Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice, J. Clin. Invest., 122, 70, 10.1172/JCI43713 Bonin, 1989, Interleukin-1 promotes proliferation of vascular smooth muscle cells in coordination with PDGF or a monocyte derived growth factor, Exp. Cell Res., 181, 475, 10.1016/0014-4827(89)90104-3 Chang, 2014, Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS), Arthritis Rheum., 66, 3227, 10.1002/art.38811 Cohen, 2012, A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation, Ann. Rheum. Dis., 71, 2059, 10.1136/annrheumdis-2012-201658 Dinarello, 2012, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases, Nat. Rev. Drug Discov., 11, 633, 10.1038/nrd3800 Fettelschoss, 2011, Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression, Proc. Natl. Acad. Sci. U. S. A., 108, 18055, 10.1073/pnas.1109176108 Freigang, 2013, Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis, Nat. Immunol., 14, 1045, 10.1038/ni.2704 Goldbach-Mansky, 2006, Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition, N. Engl. J. Med., 355, 581, 10.1056/NEJMoa055137 Gordon, 2009, When children with Kawasaki disease grow up myocardial and vascular complications in adulthood, J. Am. Coll. Cardiol., 54, 1911, 10.1016/j.jacc.2009.04.102 Hoang, 2014, Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease, Genome Med., 6, 541, 10.1186/s13073-014-0102-6 Hoffman, 2009, Therapy of autoinflammatory syndromes, J. Allergy Clin. Immunol., 124, 1129, 10.1016/j.jaci.2009.11.001 Horng, 2014, Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome, Trends Immunol., 10.1016/j.it.2014.02.007 Kamari, 2011, Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1α, Biochem. Biophys. Res. Commun., 405, 197, 10.1016/j.bbrc.2011.01.008 Kato, 1996, Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients, Circulation, 94, 1379, 10.1161/01.CIR.94.6.1379 Kuemmerle-Deschner, 2011, Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome, Arthritis Rheum., 63, 840, 10.1002/art.30149 Kuo, 2014, Single-nucleotide polymorphism rs7251246 in ITPKC is associated with susceptibility and coronary artery lesions in Kawasaki disease, PLoS One, 9, 10.1371/journal.pone.0091118 Lee, 2012, The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca(2+) and cAMP, Nature, 10.1038/nature11588 Lee, 2012, Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease, Circulation, 125, 1542, 10.1161/CIRCULATIONAHA.111.072769 Lee, 2012, Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease, Circulation, 125, 1542, 10.1161/CIRCULATIONAHA.111.072769 Lee, 2015, IL-1 signaling is critically required in stromal cells in Kawasaki disease vasculitis mouse model: role of both IL-1alpha and IL-1beta, Arterioscler. Thromb. Vasc. Biol., 35, 2605, 10.1161/ATVBAHA.115.306475 Lehman, 1985, Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension, Arthritis Rheum., 28, 652, 10.1002/art.1780280609 Leung, 1989, Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease, Lancet, 2, 1298, 10.1016/S0140-6736(89)91910-7 Lou, 2012, A functional polymorphism, rs28493229, in ITPKC and risk of Kawasaki disease: an integrated meta-analysis, Mol. Biol. Rep., 10.1007/s11033-012-2022-0 Matsubara, 2006, A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents, Arthritis Rheum., 54, 2314, 10.1002/art.21965 Maury, 1988, Circulating interleukin-1 beta in patients with Kawasaki disease, N. Engl. J. Med., 319, 1670, 10.1056/NEJM198812223192515 McCrindle, 2009, Kawasaki disease: a childhood disease with important consequences into adulthood, Circulation, 120, 6, 10.1161/CIRCULATIONAHA.109.874800 Minkis, 2012, Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis, Arch. Dermatol., 148, 747, 10.1001/archdermatol.2011.3208 Murakami, 2012, Critical role for calcium mobilization in activation of the NLRP3 inflammasome, Proc. Natl. Acad. Sci., 10.1073/pnas.1117765109 Neven, 2010, Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome, Arthritis Rheum., 62, 258, 10.1002/art.25057 Newburger, 1986, The treatment of Kawasaki syndrome with intravenous gamma globulin, N. Engl. J. Med., 315, 341, 10.1056/NEJM198608073150601 Nigrovic, 2011, Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series, Arthritis Rheum., 63, 545, 10.1002/art.30128 NIH and DAIDS. (2009). "Division of AIDS table for grading the severity of adult and pediatric adverse events." from http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf. Onouchi, 2008, ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms, Nat. Genet., 40, 35, 10.1038/ng.2007.59 Opal, 1997, Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group, Crit. Care Med., 25, 1115, 10.1097/00003246-199707000-00010 Paccaud, 2014, Neonatal treatment of CINCA syndrome, Pediatr. Rheumatol. Online J., 12, 52, 10.1186/1546-0096-12-52 Popper, 2007, Gene-expression patterns reveal underlying biological processes in Kawasaki disease, Genome Biol., 8, R261, 10.1186/gb-2007-8-12-r261 Rada, 2014, NLRP3 inflammasome activation and interleukin-1β release in macrophages require calcium but are independent of calcium-activated NADPH oxidases, Inflamm. Res., 10.1007/s00011-014-0756-y Record, 2011, Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series, J. Rheumatol., 38, 180, 10.3899/jrheum.100726 Ringold, 2013, Arthritis Rheum., 65, 2499, 10.1002/art.38092 Rosenkranz, 2005, TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease, Circulation, 112, 2966, 10.1161/CIRCULATIONAHA.105.537530 Rossi-Semerano, 2013, First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra, Pediatrics, 132, e1043, 10.1542/peds.2012-3935 Ruiz Gomez, 2012, Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency, Pediatrics, 129, e535, 10.1542/peds.2010-2192 Sasu, 2000, Essential roles of IkappaB kinases alpha and beta in serum- and IL-1-induced human VSMC proliferation, Am. J. Physiol. Heart Circ. Physiol., 278, H1823, 10.1152/ajpheart.2000.278.6.H1823 Schulte, 2009, Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease, J. Immunol., 183, 5311, 10.4049/jimmunol.0901395 Shafferman, 2014, High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report, Pediatr. Rheumatol. Online J., 12, 26, 10.1186/1546-0096-12-26 Sibley, 2012, Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes, Arthritis Rheum., 64, 2375, 10.1002/art.34409 Stenerson, 2011, The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist, Arthritis Rheum., 63, 4018, 10.1002/art.30565 Tanaka, 1979, Pathological study of Kawasaki disease (MCLS): with special reference to sequelae, Jpn. J. Med. Sci. Biol., 32, 245 Tremoulet, 2015, Anakinra treatment for IVIG-resistant Kawasaki disease patient with coronary artery aneurysms, Clin. Exp. Tremoulet, 2008, Resistance to intravenous immunoglobulin in children with Kawasaki disease, J. Pediatr., 153, 117, 10.1016/j.jpeds.2007.12.021 Yeung, 2007, Lessons learned from an animal model of Kawasaki disease, Clin. Exp. Rheumatol., 25, S69 Yonesaka, 1989, Endomyocardial biopsy in children with Kawasaki disease, Acta Paediatr. Jpn., 31, 706, 10.1111/j.1442-200X.1989.tb01384.x Urien, 2013, Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes, BMC Pharmacol. Toxicol., 14, 40, 10.1186/2050-6511-14-40